Aldeyra gets a win in its second pivotal dry eye trial of reproxalap, but only after some serious tinkering.
A pivotal failure sees the group tinker with a second phase 3 trial, and the delay looks like good news for Bausch.
The $6.5bn price – biopharma’s biggest buyout of the year so far – shows how competitive the anti-FcRn space has become.
A new mechanism for certain autoimmune conditions takes a big step forward with impressive pivotal data on Argenx’s efgartigimod.
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.